Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interaction between cisplatin and mesna in mice.

R T Dorr1, K Lagel

  • 1Arizona Cancer Center, Department of Internal Medicine, College of Medicine, University of Arizona, Tucson.

Journal of Cancer Research and Clinical Oncology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chemistry and pharmacology of imexon and related cyanoaziridines.

Current medicinal chemistry·2012
Same author

Adult rat myocardial slices: A tool for studies of comparative cardiotoxicity.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.

Bone marrow transplantation·2003
Same author

Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.

Journal of medicinal chemistry·2001
Same author

Life sciences flight hardware development for the International Space Station.

Advances in space research : the official journal of the Committee on Space Research (COSPAR)·2001
Same author

Drug interactions with the taxanes: clinical implications.

Cancer treatment reviews·2001

The uroprotectant mesna protects mice from high-dose cisplatin toxicity when administered shortly after the drug. However, mixing mesna directly with cisplatin reduces its cancer-fighting effectiveness.

Area of Science:

  • Oncology
  • Pharmacology
  • Toxicology

Background:

  • Cisplatin is a potent chemotherapy drug with significant toxicity.
  • Mesna is a uroprotectant used to mitigate chemotherapy-induced bladder toxicity.

Purpose of the Study:

  • To investigate the protective effects of mesna against cisplatin lethality.
  • To evaluate the impact of mesna administration timing on cisplatin's antitumor efficacy.

Main Methods:

  • Adult CD-1 mice and DBA/2J mice were used.
  • Mesna was administered concurrently with or after cisplatin in non-tumor-bearing mice to assess survival.
  • Mesna was administered concurrently with or after cisplatin in a leukemia tumor model to assess antitumor effects.

Main Results:

Related Experiment Videos

  • Mesna significantly increased survival in mice treated with high-dose cisplatin when given 5 minutes after cisplatin.
  • Directly mixing mesna with cisplatin reduced its antitumor activity against P-388 leukemia in mice.
  • Administering mesna 5 minutes after cisplatin did not compromise its anticancer efficacy in the tumor model.

Conclusions:

  • Mesna can protect against cisplatin-induced lethality when administered shortly after chemotherapy.
  • The timing of mesna administration is critical; concurrent administration with cisplatin may reduce therapeutic efficacy.
  • Mesna may directly inactivate cisplatin in vitro, but this interaction might be avoided in vivo with spaced administration.